Drug Trial Radar · NCT07610798
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
178
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
May 2029
Study completion May 2029
Sponsor
- Lead sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.
Conditions
- Advance Solid Tumors
- Colon and Rectal Cancer
- Non - Small Cell Lung Cancer NSCLC
- Pancreatic Adenocarcinoma Advanced or Metastatic
- Ovarian Cancer
- Endometrial Cancer
- Biliary Cancers
Interventions
INV-8989Drug
INV-8989 is admistered once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of participants with treatment-emergent adverse events (TEAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0Time frame: 12 months
- Phase 1: Maximum tolerated dose (MTD)Time frame: Within first 21 days of treatment
- Phase 1: Recommended dose range (RDR) and/or Recommended Phase Ⅱ dose (RP2D)Time frame: 12 months
- Phase 2: Evaluate overall response rate (ORR)Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.